a website banner telling users to subscribe to it's newsletter

Ora and Singapore Eye Research Institute Partner to Advance Ophthalmic Research

Ora and Singapore Eye Research Institute Partner to Advance Ophthalmic Research

May 07, 2024

Contract Research Organization (CRO) Ora Inc. announced a new strategic partnership with the Singapore Eye Research Institute (SERI) to bolster support for early-stage innovators in ophthalmology. This collaboration is set to enhance the development of therapeutic candidates in various ocular-specific therapeutic areas.

Partnership Details Remain Confidential

While the financial details of the partnership remain undisclosed, the alliance promises significant advancements in ophthalmic research. SERI is renowned for its nonclinical ophthalmic animal studies and specializes in the development and application of translatable ocular animal models across different species. This expertise will be pivotal in supporting Ora’s biopharmaceutical and device clients to hasten their therapeutic developments.

Key Benefits of the SERI-Ora Collaboration

The benefits of this partnership, as outlined by Ora, are multifaceted:

Comprehensive Preclinical Services: SERI’s expertise ensures meticulous and comprehensive preclinical evaluations.

Breadth of Models: SERI offers a variety of non-GLP models for systemic safety, toxicity, ocular safety, and efficacy, covering both anterior and posterior segments of the eye.

Reduced Timelines: The partnership grants expedited access to preclinical evaluations, leveraging world-class expertise.

Quality Assurance: SERI is AALAC accredited and adheres to the highest standards, ensuring the reliability and ethical conduct of all preclinical studies.

Expanded Capacity: This collaboration broadens Ora’s research offerings and enhances the level of expertise available to their clients.

Leadership Perspectives on the Partnership

Stuart Abelson, chairman and CEO of Ora, expressed his enthusiasm about the partnership. "SERI's outstanding reputation and their proficiency in conducting preclinical studies led by Associate Professor Veluchamy A. Barathi align perfectly with the mission of Ora,” he said. “By combining our strengths, we are poised to accelerate the development of innovative therapies at all stages, furthering SERI’s mission as a global center of excellence."

Vision for Global Excellence in Ophthalmic Research

Professor Jodhbir Mehta, MD, executive director of SERI and deputy chief executive officer (Research) at SNEC, also shared his excitement about the collaboration. "We are excited to embark on this pivotal partnership with Ora. This collaboration propels us toward realizing SERI’s vision of becoming an international center of excellence in eye and vision research," he noted. "Our SERI scientists rank among the top 2% globally in ophthalmology, and our unprecedented impact factor in scientific publications showcase our commitment to advancing eye care. By seamlessly integrating our expertise with Ora’s, we aim to provide unmatched preclinical capabilities, accelerating the development of innovative ophthalmic therapies and reinforcing our position as leaders in translating basic science to clinical applications for sight-threatening disorders.”

This partnership marks a significant step forward in the field of ophthalmic research, promising enhanced support and accelerated development of innovative treatments for eye disorders.